There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Hill-Rom (HRC) and Assembly Biosciences (ASMB) with bullish sentiments.
Hill-Rom (HRC)
Needham analyst Michael Matson reiterated a Buy rating on Hill-Rom today and set a price target of $125. The company’s shares closed yesterday at $100.06.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 7.4% and a 61.4% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Merit Medical Systems.
Currently, the analyst consensus on Hill-Rom is a Moderate Buy with an average price target of $120.
See today’s analyst top recommended stocks >>
Assembly Biosciences (ASMB)
In a report released today, Raju Prasad from William Blair maintained a Buy rating on Assembly Biosciences. The company’s shares closed yesterday at $11.86, close to its 52-week low of $11.49.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 13.6% and a 49.0% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Allogene Therapeutics Inc.
The the analyst consensus on Assembly Biosciences is currently a Moderate Buy rating.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
